βIII-tubulin can act as a brake on extrinsic apoptosis in pancreatic cancer
| dc.contributor.author | Sharbeen, George | |
| dc.contributor.author | Kokkinos, John | |
| dc.contributor.author | Schulstad, Grace | |
| dc.contributor.author | Pandzic, Elvis | |
| dc.contributor.author | Youkhana, Janet | |
| dc.contributor.author | Ma, Zerong | |
| dc.contributor.author | Ignacio, Rosa Mistica C. | |
| dc.contributor.author | Raina, Aparna S. | |
| dc.contributor.author | Chiang, Shannon | |
| dc.contributor.author | Boyer, Cyrille | |
| dc.contributor.author | Haghighi, Koroush S. | |
| dc.contributor.author | Gunawarman, Matthew | |
| dc.contributor.author | Goldstein, David | |
| dc.contributor.author | Gebski, Val | |
| dc.contributor.author | Pajic, Marina | |
| dc.contributor.author | Davis, Meagan E. | |
| dc.contributor.author | Arkell, Oliver S. M. | |
| dc.contributor.author | Kopecky, Chantal | |
| dc.contributor.author | Gonzales-Aloy, Estrella | |
| dc.contributor.author | Ishak, Alexander | |
| dc.contributor.author | Erkan, Mert | |
| dc.contributor.author | Morton, Jennifer P. | |
| dc.contributor.author | Kavallaris, Maria | |
| dc.contributor.author | Gunning, Peter W. | |
| dc.contributor.author | Hardeman, Edna C. | |
| dc.contributor.author | Johns, Amber | |
| dc.contributor.author | Gill, Anthony J. | |
| dc.contributor.author | Whan, Renee M. | |
| dc.contributor.author | Mawson, Amanda | |
| dc.contributor.author | Pitiyarachchi, Omali | |
| dc.contributor.author | McCarroll, Joshua A. | |
| dc.contributor.author | Phillips, Phoebe A. | |
| dc.date.accessioned | 2026-11-05T11:07:18Z | |
| dc.date.issued | 2026 | |
| dc.description.abstract | The microtubule protein beta III-tubulin is a prognostic, pro-survival, and chemoresistance factor in multiple malignancies, including pancreatic ductal adenocarcinoma (PDAC). However, the precise survival mechanisms controlled by beta III-tubulin in cancer remain unknown. Here, we discovered a link between beta III-tubulin and the activation of caspase 8-mediated extrinsic apoptosis. Silencing beta III-tubulin in PDAC cells activated caspase 8, leading to decreased cell viability and growth both in vitro and in vivo. beta III-tubulin knockdown also increased the sensitivity of PDAC cells to extrinsic cell death signals, including TNF-related apoptosis-inducing ligand (TRAIL), TNF alpha, and FasL. Furthermore, we demonstrated that beta III-tubulin knockdown in PDAC cells, in the absence or presence of TRAIL, increased diffusion and clustering of the TRAIL death receptor DR5 at the cell membrane, inducing extrinsic apoptosis. Nanoparticle delivery of beta III-tubulin siRNA to mouse PDAC tumours reduced tumour growth and increased responsiveness to TRAIL therapy. In patient-derived human PDAC explants, beta III-tubulin silencing reduced tumour cell frequency and improved sensitivity to TRAIL. Finally, we showed that high beta III-tubulin expression in the human PDAC stroma was independently prognostic for poor overall survival. Taken together, silencing beta III-tubulin represents an innovative strategy to activate a suicide signal in PDAC cells and render them more sensitive to microenvironment- and chemotherapy-derived death signals. | |
| dc.description.issue | 1 | |
| dc.description.pages | 547 | |
| dc.description.sponsorship | National Health and Medical Research Council Ideas Grant (Phillips, Sharbeen, APP2002707); NHMRC project grant (Phillips, McCarroll, Goldstein, APP1144108); Tour de Cure Senior Research Grant (Phillips, McCarroll, Goldstein, RSP-235-2020); Tour de Cure Pioneering Research Grant (Sharbeen, Phillips, Goldstein, RSP-255-2020); Cancer Institute NSW Translational Program Grant (Phillips, Goldstein, 2020/TPG2100); Tour de Cure PhD Support Scholarship (Kokkinos, Phillips, Goldstein, RSP-011-18/19); Cancer Research UK Institute Award (Morton, A29996); Australian Government Research Training Program Scholarship and UNSW Sydney Scientia PhD Scholarship (Kokkinos); Cancer-Institute NSW Career Development Fellowship (Sharbeen, CDF181166); Maridulu Budyari Gumal Sydney Partnership for Health, Education, Research and Enterprise [SPHERE] Cancer Clinical Academic Group Senior Research Fellowship (Funded by Cancer Institute NSW Translational Cancer Research Capacity Building Grant, 2021/CBG0003, Sharbeen); NSW Health Advanced Therapeutics Impact Grant (Sharbeen, Phillips, McCarroll, Haghighi, Goldstein); Avner Pancreatic Cancer Foundation Innovation Grant (Phillips, McCarroll, Goldstein, and Sharbeen, APCF0050618); Cancer-Institute NSW ECF (Sharbeen, 13/ECF/1-to08); Cancer Institute NSW Translational Program Grant (2020/TPG2100; Goldstein, Phillips, Pajic), NSW Health Advanced Therapeutics Impact Grant (Sharbeen, Phillips, Goldstein, McCarroll); Olivia Lambert Foundation (McCarroll), and Cancer Australia (Phillips, McCarroll and Goldstein, APP1126736); Philanthropic support from Mr Paul Dainty, Dr Marjorie O'Neil, Dr Keri Spooner, and the Ippolito family: Ignazia, Ilana and Stefan. | |
| dc.description.volume | 17 | |
| dc.identifier.doi | 10.1038/s41419-026-08657-6 | |
| dc.identifier.issn | 2041-4889 | |
| dc.identifier.uri | https://doi.org/10.1038/s41419-026-08657-6 | |
| dc.identifier.uri | https://openaccess.acibadem.edu.tr/handle/11443/11438 | |
| dc.identifier.wos | WOS:001786045400001 | |
| dc.language.iso | en | |
| dc.publisher | SPRINGERNATURE | |
| dc.relation.funding | Cancer Research UK Institute Award (A29996) | |
| dc.relation.funding | Tour de Cure Senior Research Grant (RSP-235-2020) Tour de Cure Pioneering Research Grant (RSP-255-2020) Cancer Institute NSW Translational Program Grant (2020/TPG2100) Avner Pancreatic Cancer Foundation Innovation Grant (APCF0050618) Cancer Institute NSW T | |
| dc.relation.funding | - Tour de Cure Pioneering Research Grant (RSP-255-2020) - NSW health Advanced Therapeutics Impact Grant - Maridulu Budyari Gumal Sydney Partnership for Health, Education, Research and Enterprise [SPHERE] Cancer Clinical Academic Group Senior Research Fello | |
| dc.relation.funding | - Australian Government Research Training Program Scholarship and UNSW Sydney Scientia PhD Scholarship - Tour de Cure PhD Support Scholarship (RSP-011-18/19) | |
| dc.relation.funding | Department of Health | National Health and Medical Research Council (NHMRC)(National Health & Medical Research Council (NHMRC) of Australia) | |
| dc.relation.funding | Department of Health | National Health and Medical Research Council (NHMRC) [APP2002707, APP1144108] | |
| dc.relation.hasversion | 10.1038/s41419-026-08657-6 | |
| dc.relation.ispartof | CELL DEATH & DISEASE | |
| dc.subject | GENE-EXPRESSION | |
| dc.subject | NAB-PACLITAXEL | |
| dc.subject | STELLATE CELLS | |
| dc.subject | RESISTANCE | |
| dc.subject | IDENTIFICATION | |
| dc.subject | TUBB3 | |
| dc.subject | CHEMORESISTANCE | |
| dc.subject | PROLIFERATION | |
| dc.subject | TUMORIGENESIS | |
| dc.subject | GEMCITABINE | |
| dc.subject | Cell Biology | |
| dc.title | βIII-tubulin can act as a brake on extrinsic apoptosis in pancreatic cancer | |
| dc.type | Article | |
| oaire.citation.edition | Science Citation Index Expanded (SCI-EXPANDED) | |
| oaire.citation.issue | 1 | |
| oaire.citation.volume | 17 | |
| person.identifier.orcid | 0000-0001-9854-6375 | |
| person.identifier.orcid | 0000-0002-6373-1930 | |
| person.identifier.orcid | 0000-0002-5228-0919 | |
| person.identifier.rid | HNJ-2164-2023 | |
| person.identifier.rid | A-5436-2009 | |
| person.identifier.rid | AAJ-5113-2021 | |
| person.identifier.rid | F-8872-2012 | |
| person.identifier.rid | E-9058-2010 | |
| person.identifier.rid | D-4215-2015 | |
| person.identifier.rid | E-8481-2010 | |
| person.identifier.rid | J-5240-2014 |
